Els Boone

[Carlos Collet MD PhD @ColletCarlos]

#ESC2024 @escardio FAME 2: 10-year follow-up

🏪 PCI is 25% more likely to lead to better outcomes than medical therapy alone

🔑 48% of patients were tied. Nearly half the time, it won't make a big difference which one you choose.

@PCRonline @CoreAalst @CardioAalst @OptimaCTO

[Niels R. Holm @NielsRHolm]

“Hot Line 4 is very important and will probably be the highlight of the Hot Lines for many cardiovascular health professionals. It includes a series of trials – ILUMIEN IV, OCTIVUS and OCTOBER..."
@LNAndreasen @h_evald @omeedneghabat @jcspratt #cardotwitter #octfirst

[Cardiac Research @UKheartresearch]

5-year follow up of DEFINE-FLAIR (iFR vs FFR-guided revascularisation) presented by @JEscaned #EuroPCR2023

➡️ MACE higher in iFR arm (HR 1.18; CI 0.99 - 1.41, p=0.07)

➡️ All-cause death 3% higher in iFR arm (HR 1.51; CI 1.22 - 2.90)

➡️ Difference driven by CV death

[Abbott Cardiovascular @AbbottCardio]

We’d like to take a moment acknowledge Drs. @DDamario, @Vale_Frittitta, and Antonio Greco for their commitment to personalized vascular care.

Thank you for sharing your innovative projects aimed at improving #cardiovascular care for patients at #EuroPCR: https://t.co/YqPjDlo6z7

[Ziad Ali @ziadalinyc]

1/ COMBINE (OCT–FFR): Using OCT in DM to detect risk
FFR negative lesions, according to contemporary trial data, are very low risk for subsequent events. BUT...DM patients are a unique entity. What if we could use OCT, with its incredible resolution, to identify high risk - TCFA.

[Marco Valgimigli @vlgmrc]

Are you prepared for the XIENCE short DAPT program? Stay tuned...coming soon @TCTConference @Drroxmehran @DLBHATTMD